Valuation: Monte Rosa Therapeutics, Inc.

Market Cap 1.4B 1.21B 1.13B 1.04B 1.96B 133B 1.99B 13.31B 5.22B 66.33B 5.24B 5.13B 222B P/E 2026 *
-9.98x
P/E 2027 * -9x
Enterprise Value 1.4B 1.21B 1.13B 1.04B 1.96B 133B 1.99B 13.31B 5.22B 66.33B 5.24B 5.13B 222B EV / Sales 2026 *
31.4x
EV / Sales 2027 * 24x
Free-Float
99.43%
Yield 2026 *
-
Yield 2027 * -
1 day-27.16%
1 week-27.48%
1 month-31.76%
3 months-12.13%
6 months-20.88%
Current year+5.36%
1 week 14.87
Extreme 14.87
22.72
1 month 14.87
Extreme 14.87
25.16
Current year 13.69
Extreme 13.69
25.77
1 year 4.12
Extreme 4.12
25.77
3 years 2.44
Extreme 2.44
25.77
5 years 2.44
Extreme 2.44
45.56
10 years 2.44
Extreme 2.44
45.56
Manager TitleAgeSince
Chief Executive Officer 55 2019-12-31
Chief Tech/Sci/R&D Officer - 2026-03-16
Chief Operating Officer 54 2021-02-28
Director TitleAgeSince
Director/Board Member 55 2019-12-31
Director/Board Member 49 2020-03-31
Director/Board Member 57 2020-05-31
Date Insider Type Main position Quantity % Market Cap.
7/16/26 Sell

Chief Executive Officer

-9,500 0.0112%
7/15/26 Fiscal year

Chief Operating Officer

13,053 0.0155%
7/6/26 Fiscal year

Chief Technology Officer

18,000 0.0213%
Change 5-day change 1-year change 3-year change Capi.($)
-27.16%-27.48%+244.89%+143.66% 1.4B
+1.12%+1.47%+0.35%+15.84% 48.53B
-2.41%-0.90%+411.96%+472.09% 39.87B
-1.16%+12.96%+28.81%+7.27% 38.68B
-1.88%-3.03%+5.69%+66.52% 35.13B
-1.74%+5.12%+14.44%+44.64% 29.79B
-0.21%-4.04%+36.40%+126.06% 16.11B
-2.85%-3.92% - - 16.08B
+1.14%+2.72%+3.31%+16.75% 13.61B
-1.19%-1.32%-1.73%-34.97% 12.62B
Average -3.49%-1.80%+82.68%+95.32% 25.18B
Weighted average by Cap. -0.94%+1.87%+81.18%+108.41%

Financials

2026 *2027 *
Net sales 44.48M 38.66M 35.99M 33.04M 62.4M 4.25B 63.36M 424M 166M 2.11B 167M 163M 7.09B 58.17M 50.57M 47.07M 43.21M 81.61M 5.55B 82.87M 555M 218M 2.76B 218M 214M 9.27B
Net income -167M -145M -135M -124M -235M -15.97B -238M -1.6B -626M -7.95B -628M -615M -26.66B -194M -169M -157M -144M -272M -18.51B -276M -1.85B -726M -9.22B -728M -712M -30.91B
Net Debt - -
Logo Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Employees
187
Date Price Change Volume
26-07-31 $16.52 -27.16% 7,467,901
26-07-30 $22.68 +5.19% 1,690,425
26-07-29 $21.56 -2.18% 1,233,805
26-07-28 $22.04 -2.30% 1,329,706
26-07-27 $22.56 -0.97% 1,099,814
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
16.52USD
Average target price
30.67USD
Spread / Average Target
+85.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLUE Stock